Summary
116.18
-2.87
(-2.41%)
06/15/2026
Merck & Co., Inc. (MRK)Key Facts
Performance
Historical returns1D
-2.41%
1W
-0.40%
1M
5.94%
3M
3.47%
6M
20.60%
1Y
50.78%
5Y
83.17%
Snapshot
Key statisticsClose
116.18
Change
-2.87
Change %
-2.41%
Open
118.71
Day Range
115.01 – 118.95
Volume
2,963,608
Avg Vol (20d)
10,704,706
Rel Vol
0.28x
52W Range
74.18 - 123.33
vs 52W High
-5.80%
vs 52W Low
56.61%
Gap
-1.20
Market Cap
USD 215.38B
Beta
0.32
Dividend Yield
2.37%
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
Financial SnapshotFY 2025
Full financialsRevenue
USD 64.93B
+1.2% YoY
Net Income
USD 18.25B
+6.5% YoY
EPS
7.30
+8.0% YoY
Gross Margin
72.0%
Operating Margin
36.2%
Net Margin
28.1%
EBITDA
USD 29.32B
Free Cash Flow
USD 12.36B
19.0% margin
ROE
34.7%
ROA
13.3%
Debt / Equity
0.96x
net debt USD 35.97B
Cash & Equiv.
USD 14.57B
Fundamental Ratings
MainB
RecommendedNeutral
DCFBuy
ROEStrong Buy
ROAStrong Buy
Debt/EquityStrong Sell
P/EStrong Sell
P/BStrong Sell
Latest Earnings
- MRK reported last earnings on 2026-04-30.
- EPS of $-1.28 vs $-1.47 estimated — surprise $0.19.
- Revenue of $16,286M vs $15,846M estimated — surprise $440M.
News
All newsFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves KEYTRUDA® and KEYTRUDA QLEXTM , Each With WELIREG®, for Adjuvant Treatment of Certain Patients With ccRCC.
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the closing of the recent trading day, Merck (MRK) stood at $120.76, denoting a +1.4% move from the preceding trading day.
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.
Merck Animal Health to Acquire TARGAN
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in...
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals.
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
On Monday, Gilead Sciences Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) on Monday discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial evaluating Trodelvy plus Keytruda in previously untreated metastatic non-small cell lung cancer with high PD-L1 expression, following a Data Monitoring...
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
More employers and health plans are balking at paying for costly GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and the treatment of obesity, according to a new report.
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the Phase 3 ISLEND-1 and ISLEND-2 trials with the...
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
RAHWAY, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's Trodelvy®...
Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health
SAN DIEGO--(BUSINESS WIRE)-- #animalhealth--Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health.
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
After years of lagging the market, healthcare may be taking on a new role in investor portfolios.
The Smartest Dividend ETF to Buy With $1,000 Right Now -- and It's Up 19% in 2026
This ETF's dividend yield was recently a solid 3.25%, about three times that of the S&P 500. Its growth rate has been better than that of many dividend-focused funds.
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year
The seasonal strength lines up with major medical and scientific conferences that cluster during this period.